Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000363327

Medchemexpress LLC CBP/p300-IN-19 hydrochloride | 2592638-14-5 | 99.0% | 514.01 | 25 MG
SDP

Catalog No. 5000363327
Encompass_Preferred

CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 μM for p300-HAT, CBP-HAT, PCAF, and Myst3, respectively. It also demonstrates antitumor activity.

  • Potent and selective p300/CBP HAT inhibitor
  • IC50s: 1.4 μM (p300-HAT), 2.2 μM (CBP-HAT), >100 μM (PCAF), >100 μM (Myst3)
  • Shows antitumor activity
  • Shows antiproliferative activity with EC50s in the micromolar range for various cell lines (MCF-7, MDA-MB231, LNCaP, PC-3, PANC-1, MDA-PANC-28, Molm-13, MV4;11, RPMI-8226 cells)
  • Dose-dependently inhibits the acetylation of H3K18, H3K9, and K27

Catalog No. 50-003-63327 Supplier Medchemexpress LLC Supplier No. 25MGHY146277A
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

CBP/p300-IN-19 hydrochloride is a potent and selective p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 μM for p300-HAT, CBP-HAT, PCAF, and Myst3, respectively. It also demonstrates antitumor activity.

  • Potent and selective p300/CBP HAT inhibitor
  • IC50s: 1.4 μM (p300-HAT), 2.2 μM (CBP-HAT), >100 μM (PCAF), >100 μM (Myst3)
  • Shows antitumor activity
  • Shows antiproliferative activity with EC50s in the micromolar range for various cell lines (MCF-7, MDA-MB231, LNCaP, PC-3, PANC-1, MDA-PANC-28, Molm-13, MV4;11, RPMI-8226 cells)
  • Dose-dependently inhibits the acetylation of H3K18, H3K9, and K27

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.